With the platform versatility and ability to create non-thermal irreversible lesions, what does the future hold for FARAPULSE™ PFA? The series concludes with the physicians discussing the importance of randomised clinical trials and large real-world registries to make informed decisions on therapy choice. Additionally, the benefits of early rhythm control to limit atrial fibrillation progression and the possibility of new patient populations being treated with what might be, the optimal energy source for cardiac ablation.
This video is sponsored by Boston Scientific.
